Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Mar. 31, 2022		53,379,307
Beginning balance at Mar. 31, 2022	$ 31,361	$ 5	$ 211,190	$ (178,638)	$ (1,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)		168,326
Stock options exercised	709		709
Restricted stock units vested (in shares)		115,731
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability (in shares)		(1,620)
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability	(6)		(6)
Issuance of common stock, net of issuance costs (in shares)		3,199,999
Issuance of common stock, net of issuance costs	15,720	$ 1	15,719
Stock-based compensation	2,342		2,342
Other comprehensive income (loss)	(136)				(136)
Net loss	(21,808)			(21,808)
Ending balance (in shares) at Dec. 31, 2022		56,861,743
Ending balance at Dec. 31, 2022	28,182	$ 6	229,954	(200,446)	(1,332)
Beginning balance (in shares) at Sep. 30, 2022		56,626,340
Beginning balance at Sep. 30, 2022	36,345	$ 6	228,178	(189,986)	(1,853)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)		154,904
Stock options exercised	653		653
Restricted stock units vested (in shares)		80,551
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability (in shares)		(52)
Stock-based compensation	1,123		1,123
Other comprehensive income (loss)	521				521
Net loss	(10,460)			(10,460)
Ending balance (in shares) at Dec. 31, 2022		56,861,743
Ending balance at Dec. 31, 2022	$ 28,182	$ 6	229,954	(200,446)	(1,332)
Beginning balance (in shares) at Mar. 31, 2023	57,047,013	57,047,013
Beginning balance at Mar. 31, 2023	$ 19,615	$ 6	230,272	(209,236)	(1,427)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock units vested (in shares)		475,940
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability (in shares)		(116,883)
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability	(374)		(374)
Stock warrant exercise and deemed dividend related to warrant modification, net of issuance costs (Note 8) (in shares)		2,885,120
Stock warrant exercise and deemed dividend related to warrant modification, net of issuance costs (Note 8)	10,094		11,684	(1,590)
Deemed dividend related to issuance of Inducement Warrants (Note 8)	0		6,743	(6,743)
Issuance of common stock, net of issuance costs (in shares)		2,904,758
Issuance of common stock, net of issuance costs	9,569		9,569
Stock-based compensation	4,425		4,425
Other comprehensive income (loss)	(502)				(502)
Net loss	$ (24,577)			(24,577)
Ending balance (in shares) at Dec. 31, 2023	63,195,948	63,195,948
Ending balance at Dec. 31, 2023	$ 18,250	$ 6	262,319	(242,146)	(1,929)
Beginning balance (in shares) at Sep. 30, 2023		61,981,134
Beginning balance at Sep. 30, 2023	23,691	$ 6	255,249	(229,424)	(2,140)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock units vested (in shares)		176,380
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability (in shares)		(30,838)
Restricted stock units surrendered due to net share settlement to satisfy employee tax liability	(86)		(86)
Stock warrant exercise and deemed dividend related to warrant modification, net of issuance costs (Note 8) (in shares)		1,069,272
Stock warrant exercise and deemed dividend related to warrant modification, net of issuance costs (Note 8)	2,926		3,763	(837)
Deemed dividend related to issuance of Inducement Warrants (Note 8)	0		1,884	(1,884)
Stock-based compensation	1,509		1,509
Other comprehensive income (loss)	211				211
Net loss	$ (10,001)			(10,001)
Ending balance (in shares) at Dec. 31, 2023	63,195,948	63,195,948
Ending balance at Dec. 31, 2023	$ 18,250	$ 6	$ 262,319	$ (242,146)	$ (1,929)